These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. Sánchez JE; Sáenz NG; Rincón MR; Martín IT; Sánchez EG; Martínez MJ J Antimicrob Chemother; 2000 Aug; 46(2):283-5. PubMed ID: 10933654 [TBL] [Abstract][Full Text] [Related]
23. In vitro exposure to macrolide antibiotics in Helicobacter pylori strains isolated from children. Fujimura S; Kato S; Iinuma K; Watanabe A J Infect Chemother; 2004 Apr; 10(2):128-30. PubMed ID: 15160309 [TBL] [Abstract][Full Text] [Related]
24. In vitro activity of temafloxacin against gram-negative bacteria: an overview. Hardy DJ Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. Ani AE; Malu AO; Onah JA; Queiroz DM; Kirschner G; Rocha GA Trans R Soc Trop Med Hyg; 1999; 93(6):659-61. PubMed ID: 10717760 [TBL] [Abstract][Full Text] [Related]
27. In-vitro activity of quinolones and macrolides against mycobacteria. Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409 [TBL] [Abstract][Full Text] [Related]
28. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. Cederbrant G; Kahlmeter G; Schalén C; Kamme C J Antimicrob Chemother; 1994 Dec; 34(6):1025-9. PubMed ID: 7730216 [TBL] [Abstract][Full Text] [Related]
29. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Welsh L; Gaydos C; Quinn TC Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907 [TBL] [Abstract][Full Text] [Related]
30. Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin. Lascols C; Bryskier A; Soussy CJ; Tanković J J Antimicrob Chemother; 2001 Nov; 48(5):738-40. PubMed ID: 11679568 [No Abstract] [Full Text] [Related]
31. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. Malizia T; Tejada M; Marchetti F; Favini P; Pizzarelli G; Campa M; Senesi S J Antimicrob Chemother; 1998 Mar; 41 Suppl B():29-35. PubMed ID: 9579710 [TBL] [Abstract][Full Text] [Related]
32. Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. Goldstein EJ; Citron DM Antimicrob Agents Chemother; 1993 May; 37(5):1150-3. PubMed ID: 8390810 [TBL] [Abstract][Full Text] [Related]
33. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. Nagate T; Numata K; Hanada K; Kondo I J Clin Gastroenterol; 1990; 12 Suppl 1():S135-8. PubMed ID: 2212539 [TBL] [Abstract][Full Text] [Related]
34. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. Wise R; Brenwald NP; Andrews JM; Boswell F J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816 [TBL] [Abstract][Full Text] [Related]
35. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Yoh M; Frimpong EK; Voravuthikunchai SP; Honda T Can J Microbiol; 1999 Sep; 45(9):732-9. PubMed ID: 10526400 [TBL] [Abstract][Full Text] [Related]
37. Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. Fera MT; Carbone M; De Sarro A; Blandino G; Riggio G; Cusumano V; De Sarro GB; Ciliberti FA Int J Antimicrob Agents; 1998 Nov; 10(4):285-9. PubMed ID: 9916902 [TBL] [Abstract][Full Text] [Related]
38. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. Jones RN; Doern GV; Gerlach EH; Hindler J; Erwin ME Diagn Microbiol Infect Dis; 1994 Apr; 18(4):243-9. PubMed ID: 7924221 [TBL] [Abstract][Full Text] [Related]
39. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Stout JE; Sens K; Mietzner S; Obman A; Yu VL Int J Antimicrob Agents; 2005 Apr; 25(4):302-7. PubMed ID: 15784309 [TBL] [Abstract][Full Text] [Related]
40. The macrolides: erythromycin, clarithromycin, and azithromycin. Alvarez-Elcoro S; Enzler MJ Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]